Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Banks and Pharma stocks lead the rally
Wed, 30 Oct 11:30 am

After opening in the green, the Indian Indices are trading positive in the morning session amid outperformance in mid and small cap stocks. The buying interest is the highest in Banking and Pharma stocks.

The BSE-Sensex is up 55 points and the NSE-Nifty is trading up 15 points. The BSE Mid Cap index is trading up 0.5% and the BSE Small Cap index is trading up 0.7%. The Rupee is trading at 61.45 to the US Dollar.

Most Steel stocks are trading positive today. Jindal Saw and Tata Steel are among the stocks leading the gainers. India's leading steel company, Tata Steel has announced further restructuring of its European operations. The restructuring pertains to its long products business in the United Kingdom (U.K) which produces tubes, rails and rods. The prolonged slowdown in steel demand in Europe since 2007 has resulted in this restructuring. The company confirmed that these proposals would affect the employment of up to 500 people. The sites in the U.K that would be affected are Scunthorpe, Workington and Teesside. The demand for the products manufactured at the Scunthorpe site, in particular, has been facing a serious downturn. Tata Steel, which is Europe's second largest steel producer, has faced a slowdown in steel demand since 2007. This was the same year that it acquired Corus steel in the U.K. Tata Steel is trading up 1.4% today.

Indian Pharma stocks are trading mixed today. Torrent Pharma and Panacea Biotech are leading the gainers; while Divis Laboratories and J.B. Chemicals are leading the losers. Ranbaxy Laboratories' 3QCY13 results have been disappointing. The company's consolidated sales have risen by 3% YoY to Rs 27.5bn. As per the company, the sales were impacted by the new pricing policy and trade concerns in India. Also, the absence of any post exclusively sales during the quarter led to moderate growth in sales. The company reported a loss of Rs 4.5 bn; mainly as a result of write-offs this quarter because of the US regulatory enforcements at the company's Mohali facility. During the current quarter, the company's sales from the US market rose by just 2.6% YoY to Rs 7.9bn. In the domestic market, the company reported sales of Rs 5.7 bn; which was in line with last year's corresponding quarter. Ranbaxy is trading flat today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Banks and Pharma stocks lead the rally". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.